+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Peptide Therapeutics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 128 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5669575

Market is advancing peptide-drug conjugates and cell-penetrating peptides for precise disease targeting

The Global Peptide Therapeutics Market is estimated to be USD 33.8 Bn in 2023 and is expected to reach USD 54.63 Bn by 2028 growing at a CAGR of 10.08%.

  • Peptides are short chains of amino acids that target certain biological processes in the body. They can mimic natural proteins and influence biological functions, making them potentially useful as therapies for various disorders. Compared to traditional medications, peptide-based treatments are often more targeted, efficient, and have fewer side effects.
  • The growing global incidence of cancer, cardiovascular disease, and metabolic disorders has increased the demand for effective and targeted therapy alternatives. Because of their capacity to specifically target disease-related components and processes, peptide therapies are a potential strategy. These medications are gaining popularity as viable therapeutic alternatives for people suffering from these serious diseases due to their potential for reduced side effects and increased efficacy.
  • Biotechnology and drug development advancements have resulted in new platforms for developing next-generation protein and peptide therapies. These platforms enable more stable, powerful, and selective peptide medicines to be designed, manufactured, and delivered. As pharmaceutical companies invest in these advanced methods, the peptide therapeutics market expands rapidly, attracting both research and commercial investments.
  • Biotechnology and peptide research advancements have opened the path for new drug development methods. Scientists are exploring new peptides and upgrading synthesis processes with significant R&D spending, leading to more efficient, stable, and tailored treatments. The peptide sector's continual technological innovation and financial commitment create great potential for the creation of advanced pharmaceuticals to meet unmet medical needs.
  • The peptide therapeutics market has an adequate product pipeline that includes a varied spectrum of peptide-based medications in various stages of development. The strong portfolio reflects the growing interest in peptide research among pharmaceutical and biotech companies. As promising candidates move through clinical trials and achieve regulatory approval, they provide enormous market potential, drawing investments and improving the peptide therapeutics industry's overall growth possibilities.
  • However, the market is hampered by naturally occurring peptides' poor chemical and physical stability and their short circulating plasma half-life. These constraints make developing practical peptide therapies with sustained efficacy challenging, lowering their commercial viability and needing substantial research to overcome these obstacles.
  • The presence of major safety rules controlling the development and approval of peptide therapies poses a market hurdle. Meeting these rigorous standards necessitates significant preclinical and clinical testing, substantially increasing development costs and schedules. Compliance with safety requirements is a major hurdle for companies seeking to bring peptide medications to market.

Market Segmentations

  • The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.
  • By Synthesis Technology, the Global Peptide Therapeutics Market is classified into Hybrid Phase, Liquid Phase, and Solid Phase.
  • Solid Phase Synthesis holds a larger market share. It is the favored choice for peptide therapies synthesizing due to its versatility, scalability, and automation. Solid Phase Synthesis makes production more efficient.
  • By Drug Class, the Global Peptide Therapeutics Market is classified into Calcitonin's, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin.
  • Insulins hold a significant market share. Insulins are routinely given as a critical diabetes treatment, resulting in significant market demand. Diabetes is becoming more common, and advances in insulin formulations contribute to its market dominance.
  • By Route of Administration, the Global Peptide Therapeutics Market is classified into Parenteral and Oral.
  • Parenteral route of administration holds a larger market share. Due to their sensitivity to breakdown in the digestive system, peptide treatments are frequently delivered parenterally. The parenteral method ensures direct distribution into the bloodstream, increasing medication absorption and its effectiveness.
  • By API Type, the Global Peptide Therapeutics Market is classified into CMO and In-house.
  • In-house API production holds a significant market share. Many pharmaceutical businesses prefer in-house manufacturing to keep quality, intellectual property, and production timetables under control. In-house production remains the preferred option for established businesses with strong infrastructure and expertise.
  • By Application, the Global Peptide Therapeutics Market is classified into Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications.
  • Cancer holds a larger market share. The rising prevalence of cancer, as well as the need for more tailored and effective treatments, have resulted in increased research and investment in peptide therapeutics for oncology. Peptide-based medications may provide advantages in treating certain cancer types.
  • By End User, the Global Peptide Therapeutics Market is classified into Hospitals, Pharmaceutical Industries, and Research Laboratories.
  • Pharmaceuticals Industries hold a significant market share. Pharmaceutical companies drive the industry since they are the principal manufacturers and distributors of peptide therapies. They create and market these medications for a variety of medical ailments.
  • By Geography, the Global Peptide Therapeutics Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
  • The Americas hold a larger market share. This is due to the region's well-established healthcare infrastructure, significant research funding, and a larger frequency of chronic diseases, which has resulted in stronger demand for advanced treatment options such as peptide-based medicines.

Recent Development

  • CHOSEN by Dermatology launches Peptide Therapy Gel for intense skin repair and rejuvenation - July 2023
  • Evonik launches next-generation peptide for biopharma applications - June 2023

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Amgen Inc., Eli Lilly and Company, Novo Nordisk AS, Zealand Pharma AS, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Peptide Therapeutics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Peptide Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Peptide Therapeutics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research0
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Increasing Prevalence of Cancer, Cardiovascular Disorders, and Metabolic Disorders
4.2.2 Adoption of New Platforms That Develop Next-Generation Protein or Peptide Therapeutics
4.3 Restraints
4.3.1 Poor Chemical and Physical Stability and a Short Circulating Plasma Half-Life of Naturally Occurring Peptides
4.4 Opportunities
4.4.1 Technology Advancement and R&D Investment in New Peptides
4.4.2 Presence of a Strong Product Pipeline Portfolio
4.5 Challenges
4.5.1 Presence of Stringent Safety Regulations
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Peptide Therapeutics Market, By Synthesis Technology
6.1 Introduction
6.2 Hybrid Phase
6.3 Liquid Phase
6.4 Solid Phase
7 Global Peptide Therapeutics Market, By Drug Class
7.1 Introduction
7.2 Calcitonin's
7.3 Glucagon & Analogs
7.4 Insulins
7.5 Luteinizing Hormone-Releasing Hormone
7.6 Somatostatins
7.7 Vasopressin
8 Global Peptide Therapeutics Market, By Route of Administration
8.1 Introduction
8.2 Parenteral
8.3 Oral
9 Global Peptide Therapeutics Market, By API Type
9.1 Introduction
9.2 CMO
9.3 In-House
10 Global Peptide Therapeutics Market, By Application
10.1 Introduction
10.2 Gastrointestinal Disorders
10.3 Neurological Disorders
10.4 Metabolic Disorders
10.5 Cancer
10.6 Other Applications
11 Global Peptide Therapeutics Market, By End User
11.1 Introduction
11.2 Hospitals
11.3 Pharmaceutical Industries
11.4 Research Laboratories
12 America’s Peptide Therapeutics Market
12.1 Introduction
12.2 Argentina
12.3 Brazil
12.4 Canada
12.5 Chile
12.6 Colombia
12.7 Mexico
12.8 Peru
12.9 United States
12.10 Rest of Americas
13 Europe's Peptide Therapeutics Market
13.1 Introduction
13.2 Austria
13.3 Belgium
13.4 Denmark
13.5 Finland
13.6 France
13.7 Germany
13.8 Ireland
13.9 Italy
13.10 Luxembourg
13.11 Netherlands
13.12 Norway
13.13 Poland
13.14 Russia
13.15 Spain
13.16 Sweden
13.17 Switzerland
13.18 United Kingdom
13.19 Rest of Europe
14 Middle East and Africa's Peptide Therapeutics Market
14.1 Introduction
14.2 Egypt
14.3 Israel
14.4 Qatar
14.5 Nigeria
14.6 Saudi Arabia
14.7 South Africa
14.8 United Arab Emirates
14.9 Rest of MEA
15 APAC's Peptide Therapeutics Market
15.1 Introduction
15.2 Australia
15.3 Bangladesh
15.4 China
15.5 India
15.6 Indonesia
15.7 Japan
15.8 Malaysia
15.9 Philippines
15.10 Singapore
15.11 South Korea
15.12 Sri Lanka
15.13 Thailand
15.14 Taiwan
15.15 Rest of Asia-Pacific
16 Competitive Landscape
16.1 Competitive Quadrant
16.2 Market Share Analysis
17 Company Profiles
17.1 AmbioPharm Inc.
17.1.1 Company Overview
17.1.2 Company Snapshot
17.1.3 Product Overview
17.1.4 Business Overview
17.1.5 SWOT Analysis
17.1.6 Recent Developments
17.2 Amgen Inc.
17.2.1 Company Overview
17.2.2 Company Snapshot
17.2.3 Product Overview
17.2.4 Business Overview
17.2.5 SWOT Analysis
17.2.6 Recent Developments
17.3 AstraZeneca PLC
17.3.1 Company Overview
17.3.2 Company Snapshot
17.3.3 Product Overview
17.3.4 Business Overview
17.3.5 SWOT Analysis
17.3.6 Recent Developments
17.4 Bachem Holding Ag
17.4.1 Company Overview
17.4.2 Company Snapshot
17.4.3 Product Overview
17.4.4 Business Overview
17.4.5 SWOT Analysis
17.4.6 Recent Developments
17.5 Bristol-Myers Squibb Company
17.5.1 Company Overview
17.5.2 Company Snapshot
17.5.3 Product Overview
17.5.4 Business Overview
17.5.5 SWOT Analysis
17.5.6 Recent Developments
17.6 Corden Pharma GmbH
17.6.1 Company Overview
17.6.2 Company Snapshot
17.6.3 Product Overview
17.6.4 Business Overview
17.6.5 SWOT Analysis
17.6.6 Recent Developments
17.7 Eli Lilly and Company
17.7.1 Company Overview
17.7.2 Company Snapshot
17.7.3 Product Overview
17.7.4 Business Overview
17.7.5 SWOT Analysis
17.7.6 Recent Developments
17.8 F. Hoffmann-La Roche Ag
17.8.1 Company Overview
17.8.2 Company Snapshot
17.8.3 Product Overview
17.8.4 Business Overview
17.8.5 SWOT Analysis
17.8.6 Recent Developments
17.9 GSK PLC
17.9.1 Company Overview
17.9.2 Company Snapshot
17.9.3 Product Overview
17.9.4 Business Overview
17.9.5 SWOT Analysis
17.9.6 Recent Developments
17.10 Hemmo Pharmaceuticals Pvt. Ltd.
17.10.1 Company Overview
17.10.2 Company Snapshot
17.10.3 Product Overview
17.10.4 Business Overview
17.10.5 SWOT Analysis
17.10.6 Recent Developments
17.11 Ipsen SA
17.11.1 Company Overview
17.11.2 Company Snapshot
17.11.3 Product Overview
17.11.4 Business Overview
17.11.5 SWOT Analysis
17.11.6 Recent Developments
17.12 Merck & Co., Inc.
17.12.1 Company Overview
17.12.2 Company Snapshot
17.12.3 Product Overview
17.12.4 Business Overview
17.12.5 SWOT Analysis
17.12.6 Recent Developments
17.13 Novartis International Ag
17.13.1 Company Overview
17.13.2 Company Snapshot
17.13.3 Product Overview
17.13.4 Business Overview
17.13.5 SWOT Analysis
17.13.6 Recent Developments
17.14 Novo Nordisk AS
17.14.1 Company Overview
17.14.2 Company Snapshot
17.14.3 Product Overview
17.14.4 Business Overview
17.14.5 SWOT Analysis
17.14.6 Recent Developments
17.15 Pfizer Inc.
17.15.1 Company Overview
17.15.2 Company Snapshot
17.15.3 Product Overview
17.15.4 Business Overview
17.15.5 SWOT Analysis
17.15.6 Recent Developments
17.16 PolyPeptide Group
17.16.1 Company Overview
17.16.2 Company Snapshot
17.16.3 Product Overview
17.16.4 Business Overview
17.16.5 SWOT Analysis
17.16.6 Recent Developments
17.17 Sanofi SA
17.17.1 Company Overview
17.17.2 Company Snapshot
17.17.3 Product Overview
17.17.4 Business Overview
17.17.5 SWOT Analysis
17.17.6 Recent Developments
17.18 Takeda Pharmaceutical Co.Ltd.
17.18.1 Company Overview
17.18.2 Company Snapshot
17.18.3 Product Overview
17.18.4 Business Overview
17.18.5 SWOT Analysis
17.18.6 Recent Developments
17.19 Teva Pharmaceutical Industries Ltd.
17.19.1 Company Overview
17.19.2 Company Snapshot
17.19.3 Product Overview
17.19.4 Business Overview
17.19.5 SWOT Analysis
17.19.6 Recent Developments
17.20 Zealand Pharma AS
17.20.1 Company Overview
17.20.2 Company Snapshot
17.20.3 Product Overview
17.20.4 Business Overview
17.20.5 SWOT Analysis
17.20.6 Recent Developments
18 Appendix
18.1 Self-Assessment Form

Companies Mentioned

  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding Ag
  • Bristol-Myers Squibb Company
  • Corden Pharma GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ag
  • GSK PLC
  • Hemmo Pharmaceuticals Pvt. Ltd.
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis International Ag
  • Novo Nordisk AS
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi SA
  • Takeda Pharmaceutical Co.Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma AS

Table Information